Neurocrine Biosciences | NBIX - Trade Creditors

Stock Price
129.76
Daily Change
-0.95 -0.73%
Monthly
-0.26%
Yearly
17.63%
Q1 Forecast
125.86

Neurocrine Biosciences reported $545.5M in Trade Creditors for its fiscal quarter ending in December of 2025.





Trade Creditors Change Date
AbbVie USD 3.59B 28.65B Dec/2025
Acadia Pharmaceuticals USD 10.9M 10.84M Dec/2025
Agios Pharmaceuticals USD 18.36M 1.2M Dec/2025
ALKERMES USD 107.95M 39.95M Dec/2025
Alnylam Pharmaceuticals USD 115.72M 1.87M Dec/2025
Amgen USD 20.89B 1.25B Dec/2025
Biogen USD 432M 18.9M Dec/2025
BioMarin Pharmaceutical USD 759.03M 39.41M Dec/2025
Cytokinetics USD 105.62M 83.53M Dec/2025
Enanta Pharmaceuticals USD 1.88M 63K Dec/2025
Exelixis USD 29.62M 4.27M Dec/2025
Gilead Sciences USD 808M 226M Sep/2025
Halozyme Therapeutics USD 20.9M 5.54M Dec/2025
Incyte USD 1.63B 1.46B Dec/2025
Ionis Pharmaceuticals USD 14.33M 8.47M Sep/2025
Nektar Therapeutics USD 15.56M 1.28M Sep/2025
Neurocrine Biosciences USD 545.5M 425.6M Dec/2025
Pfizer USD 5.02B 142M Sep/2025
Prothena USD 10.5M 1.7M Sep/2025
Regeneron Pharmaceuticals USD 5.83B 4.93B Dec/2025
Repligen USD 30.01M 584K Dec/2025
Rigel Pharmaceuticals USD 3.85M 3.44M Sep/2025
Sarepta Therapeutics USD 280.84M 186.83M Dec/2025
Teva Pharmaceutical Industries USD 2.53B 176M Dec/2025
Ultragenyx Pharmaceutical USD 40.57M 6.33M Sep/2025
Vertex Pharmaceuticals USD 3.43B 600.9M Dec/2025
Xoma USD 2.65M 1.52M Sep/2025